COVID Vaccine: After Pfizer and Serum Institute, Bharat Biotech applies for emergency use of Covaxin

Bharat Biotech on Monday applied for emergency use authorisation for its indigenously developed COVID-19 vaccine 'Covaxin' to Drugs Controller General of India (DCGI), officials said. Bharat Biotech is the third company which has applied for emergency use authorisation for its vaccine. It is the second Indian company to apply for emergency use authorisation after the Serum Institute of India applied for such use for a vaccine developed by Oxford University and AstraZeneca. Pfizer had applied for the emergency use authorisation to DCGI on December 6.